Co-Commercialization definition

Co-Commercialization means the joint Commercialization of a Collaboration Product in the Field, in the Territory by both Parties under the terms of this Agreement. “Co-Commercialize,” when used as a verb, means to engage in such Co-Commercialization.

Co-Commercialization means, with respect to a Product, conducting activities to market and sell such Product, including: · field force detailing Products to Lipid Specialists; · providing input on medical affairs communications; · providing input on marketing materials and strategy; · participating in field force trainings; and · participating in Novartis presence at medical meetings and congresses.

Co-Commercialization or “Co-Commercialize” means the activities conducted by GSK and OncoMed, as set forth in Article 6, to Commercialize Collaboration Compound(s).

Examples of Co-Commercialization in a sentence

• Following submission of the first NDA for a Product or at such earlier time as AstraZeneca may request, the Parties will negotiate and enter into an agreement (the “Co-Commercialization Agreement”) governing the Parties’ conduct of activities for Commercializing the Product in the U.S. The Co-Commercialization Agreement will be consistent with the terms of this Article 5, Exhibit I, other terms agreed by the Parties, and other customary terms for such an agreement.

• AstraZeneca will reimburse FibroGen for such costs incurred by FibroGen, plus a markup of [*] to be applied to FibroGen’s [*] costs only, all pursuant to more detailed provisions to be included in the Co-Commercialization Agreement.

• The Parties will coordinate sales force training efforts in Co-Commercialization Countries and will share training materials (and conduct joint training, where appropriate) to facilitate joint sales force training efforts.

• Representative images of the flow cytometric analysis of (A) HLA-DR and (B) HLA-I are shown.

• Commencing January 1, 2013, BMS shall have no further obligation under the Restated Agreement or the U.S. Co-Commercialization to deploy MRs to Detail Product (including, without limitation, no obligation to provide PDEs) in the United States or to deploy MSLs to conduct medical activities relating to Product in the United States.

More Definitions of Co-Commercialization

Co-Commercialization means the joint performance of the Commercialization activities and Medical Affairs Activities by the Parties with respect to the Licensed Antibody(ies) or Product(s) in the Co-Commercialization Territory, as further detailed in Section 5.3.

Co-Commercialization means Commercialization activities in or for the Shared Territory, including sales and marketing activities, Pricing Matters, the local adaptation of global or regional Promotional Materials, strategic marketing, and Medical Affairs Activities as set forth in, and subject to, the applicable Co-Commercialization Agreement, including Detailing and promotional activities (including performing sales calls) related to a Licensed Product or, as applicable, a Gilead Combination Product undertaken by personnel of either Party with respect to the Licensed Product or, as applicable, a Gilead Combination Product, in each case in the Shared Territory. For clarity, […***…]. “Co-Commercialize,” “Co-Commercializing” and “Co-Commercialized” shall have corollary meanings therefor.

Co-Commercialization or “Co-commercialize” means the Commercialization activities of the Parties with respect to the Licensed Product together in the Co- commercialization Territory.

Co-Commercialization means the joint performance of the Commercialization activities and Medical Affairs Activities by the Parties with respect to the Licensed Antibody(ies) or Product(s) in the Co- Commercialization Territory, as further detailed in Section 5.3.

Co-Commercialization means, with respect to the Product, conducting activities to market and sell such Product, including: • field force detailing the Product; • field medical which includes interactions with organized customers (e.g., payers, medical groups and integrated delivery networks) • participating in patient support and advocacy initiatives • participating in medical affairs communications; • participating in the creation and implementation of marketing materials and strategy; • participating in field force trainings; and • participating at medical meetings and congresses. Co-Commercialization opt-in principles: • Criteria required for Akcea to have the right to opt-in to Co-Commercialize the Product with Pfizer in each Major Market pursuant to Section 2.7.3. For the avoidance of doubt, if the following criteria are not met on the date upon which Akcea delivers a written notice to Pfizer exercising the right to Co-Commercialize the Product with Pfizer pursuant to Section 2.7.3, Akcea will be deemed to not have the capability to Co-Commercialize the Product with Pfizer in each Major Market pursuant to Section 2.7.3. For clarity, Akcea may not opt-in to Co-Commercialize the Product on an Indication-by-Indication basis. o [***] in the applicable Major Market o Field force coverage for each Major Market where Akcea opts in to Co-Commercialize o [***] o Ability to provide [***]% of field force detailing in each Major Market. Notwithstanding Section 4.3, Akcea cannot [***] or [***] to achieve such percentage • Fee (applied to Akcea’s [***]) provided to Akcea for Co-Commercializing the Product (for clarity, no [***] will be paid to Akcea for Co-Commercializing the Product) o A field force fully-loaded FTE rate for [***] to be [***], but not to exceed between $[***] to $[***] per calendar year (the “FF FTE Rate”). A field force fully-loaded FTE rate for [***] to be [***] for each Major Market o [***] the FF FTE Rate for the [***] the Product is Commercialized and being sold by Pfizer or its Affiliates and Akcea in each Major Market 165301880

Co-Commercialization means the act of Co-Promoting in a Co-Commercialization Country.

Co-Commercialization means the performance of the Commercialization activities by Incyte (or by Incyte and Syndax, following Syndax’s exercise of the Co-Commercialization Option and/or as otherwise provided in the Co- Commercialization Plan) with respect to the Licensed Antibody(ies) or Product(s) in the Co-Commercialization Territory, as further detailed in Section 5.2.